Stockscreener 앱 받기
62.90
1.29%
0.80
시간 외 거래:
62.90
전일 마감가:
$62.10
열려 있는:
$61.97
하루 거래량:
1.59M
Relative Volume:
0.61
시가총액:
$7.75B
수익:
$947.36M
순이익/손실:
$392.47M
주가수익비율:
20.83
EPS:
3.02
순현금흐름:
$392.71M
1주 성능:
+6.57%
1개월 성능:
+12.72%
6개월 성능:
+10.16%
1년 성능:
+15.50%
1일 변동 폭
$61.90
$63.27
1주일 범위
$58.67
$65.40
52주 변동 폭
$42.01
$70.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
HALO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
62.90 | 7.29B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-05-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 다운그레이드 | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 개시 | TD Cowen | Outperform |
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Is Halozyme Therapeutics Inc. part of any ETF3x Gain Trade Candidates - thegnnews.com
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - MSN
Halozyme up after guidance raise, Morgan Stanley upgrade - MSN
Leerink Partners Maintains Sell Rating on Halozyme with $51 Price Target - AInvest
After Golden Cross, Halozyme Therapeutics (HALO)'s Technical Outlook is Bright - Yahoo Finance
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance
Why Have Halozyme Stocks Plummeted? - TipRanks
What Does the Market Think About Halozyme Therapeutics? - 富途牛牛
A Quick Look at Today's Ratings for Halozyme Therapeutics(HALO.US), With a Forecast Between $75 to $91 - 富途牛牛
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q2 2025 Earnings Call Transcript - Insider Monkey
Results: Halozyme Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - 富途牛牛
HC Wainwright Raises Price Target for Halozyme Therapeutics to $75 - AInvest
Halozyme raises 2025 revenue guidance to $1.355B amid accelerating royalty growth and new product catalysts - MSN
Halozyme Therapeutics’ Earnings Call Highlights Robust Growth - TipRanks
Halozyme Therapeutics Surges on 86.74% Volume Spike to $360M, 329th Market Activity as Royalty Revenue Drives 41% EBITDA Jump - AInvest
Halozyme Therapeutics 2025 Q2 Earnings Surpasses Expectations, Net Income Surges 77% - AInvest
Halozyme Therapeutics (HALO): A High-Conviction Buy as Royalty-Driven Growth Accelerates - AInvest
Halozyme Therapeutics Lifts Outlook As Royalties Climb Higher - Finimize
Halozyme (HALO) Surges on Upgraded Guidance and Increased Revenue - GuruFocus
HALO: JMP Securities Raises Price Target Despite Maintaining "Ma - GuruFocus
Halozyme up after guidance raise, Morgan Stanley upgrade (HALO) - Seeking Alpha
Halozyme Therapeutics: JMP Securities Raises PT to $91 from $78, Maintains Market Outperform - AInvest
Halozyme Therapeutics Guidance Upgrade Driven by Robust Royalty Revenue, Morgan Stanley Says - MarketScreener
HALO Analyst Rating: HC Wainwright Maintains 'Buy' and Raises Pr - GuruFocus
Morgan Stanley Upgrades Halozyme Therapeutics (HALO) to Overweig - GuruFocus
Halozyme Therapeutics 2025 Q2 Earnings Surpasses Expectations with Net Income Jumping 77.1% - AInvest
Morgan Stanley Upgrades Halozyme Therapeutics to Overweight From Equalweight, Raises Price Target to $75 From $62 - MarketScreener
Halozyme Sees Price Target Boost Amid Strong Q2 Performance: Analyst Increases Target to $75, Maintains Buy Rating - AInvest
Halozyme (HALO) Sees Price Target Boost Amid Strong Q2 Performan - GuruFocus
Halozyme Therapeutics: A Masterclass in Platform-Driven Royalty Growth and Strategic Scalability - AInvest
Halozyme Therapeutics Reports Strong Q2 Earnings, Surpassing ExpectationsNews and Statistics - IndexBox
Halozyme Therapeutics: A High-Conviction Buy in the IP-Driven Biotech Revolution - AInvest
Halozyme (HALO) Reports Record Q2 Revenue and Boosts 2025 Guidan - GuruFocus
Halozyme's Q2 2025: Unpacking Contradictions in Patent Litigation, ENHANZE Impact, and Regulatory Challenges - AInvest
Why Halozyme Shares Are Moving Amid Strong Earnings - TipRanks
Halozyme (HALO) Receives Upgrade and Raised Price Target from Mo - GuruFocus
Halozyme Therapeutics stock price target raised to $91 by Citizens JMP - Investing.com Australia
Morgan Stanley upgrades Halozyme stock to Overweight on ORPHAN Cures Act - Investing.com Nigeria
Morgan Stanley upgrades Halozyme stock to Overweight on ORPHAN Cures Act By Investing.com - Investing.com South Africa
Halozyme Therapeutics: Q2 Earnings Snapshot - New Haven Register
Halozyme Therapeutics Inc (HALO) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Halozyme Therapeutics Inc (HALO) Q2 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives - GuruFocus
Halozyme Therapeutics Reports Strong Q2 2025 Results - TipRanks
Halozyme Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Decoding Halozyme Therapeutics Inc (HALO): A Strategic SWOT Insi - GuruFocus
Halozyme (HALO) Q2 EPS Jumps 69% - The Globe and Mail
Halozyme (HALO) Q2 EPS Jumps 69% - The Motley Fool
Halozyme Therapeutics: A High-Conviction Buy Amid Record Royalty Growth and Expanding Market Access - AInvest
Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Halozyme Therapeutics: Pioneering Subcutaneous Delivery and Scalable Royalty Growth in a Dynamic Biopharma Landscape - AInvest
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):